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Introduction: Opsoclonus-myoclonus syndrome is a rare autoimmune syndrome usually seen in children and very
rarely in adults. It typically presents with a triad of opsoclonus, myoclonus and ataxia, and is most often associated
with a tumor or after an infection or vaccination. Around half of all adult cases are paraneoplastic in origin, and
isolated case reports include associations with lung, breast and ovarian cancers. To the best of our knowledge, this
is the first-ever reported case of paraneoplastic opsoclonus-myoclonus syndrome occurring in association with a
nasopharyngeal carcinoma.
Case presentation: A 50-year-old British Caucasian woman presented with left-sided otalgia and subjective hearing
loss. Over the coming weeks she developed subacute confusion and dizziness, leading to recurrent falls. Her clinical
examination revealed opsoclonus, myoclonus and signs of cerebellar dysfunction. Subsequent magnetic resonance
imaging revealed a left-sided nasopharyngeal carcinoma, which was confirmed on biopsy. A tapering dose of
steroids and a five-day course of intravenous immunoglobulins, followed by a combination of chemo-radiotherapy
for the nasopharyngeal carcinoma, led to a significant clinical improvement. At six months follow-up she had no
signs of focal neurological deficit, apart from the inability to tandem walk. We believe that the typical clinical
features, presence of a tumor and response to treatment support a paraneoplastic aetiology.
Conclusions: We show that a nasopharyngeal carcinoma can be associated with adult onset opsoclonus-myoclonus
syndrome. Both neurologists and otorhinolaryngologists must be aware of such a presentation. Prognosis of the
syndrome depends on early and adequate management of the tumor, therefore prompt identification of the
syndrome and the underlying tumor is essential.
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Opsoclonus-myoclonus syndrome (OMS) is known by a
variety of names including, ‘dancing eye-dancing limb syn-
drome’ , opsoclonus-myoclonus-ataxia and Kinsbourne
syndrome, following the first description in an infant by
Marcel Kinsbourne in 1962 [1,2]. The variable nomencla-
ture for OMS reflects how patients can lack any one of
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creativecommons.org/publicdomain/zero/1.0/[3]. OMS typically presents in children between the ages
of one to four-years-old, where it is most often associated
with a paraneoplastic, immune-mediated encephalopathy
as a result of a neuroblastoma [4]. An identical presentation
may occur without a tumor when it typically occurs after
infections or vaccinations. It is less common in adults,
where up to 50% are thought to be paraneoplastic in origin
[1]. The most commonly associated tumors are non-small
cell and small cell lung carcinomas, breast cancers and
ovarian cancers [5,6]. To the best of our knowledge, this is
the first reported case of paraneoplastic OMS occurring in
association with a nasopharyngeal carcinoma.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Figure 1 T2-weighted axial magnetic resonance image depicting a
left-sided nasopharyngeal mass (arrow) and fluid filling left mastoid
air cells.
Figure 2 Whole body (18F)-fluorodeoxyglucose positron emission
tomography depicting a mass in the post-nasal space (purple box)
and an ipsilateral hypermetabolic level II lymph node (1.5×1.4cm)
(blue box).
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A 50-year-old British Caucasian woman presented to her
general practitioner with a six-month history of pain in
and around the left mastoid process and subjective mild
hearing loss. She was referred to the local district gen-
eral hospital where an ear, nose and throat exam with a
pure tone audiogram was normal, except for tenderness
over the left temporomandibular joint. Whilst awaiting a
head and neck magnetic resonance imaging scan (MRI)
she presented to her local hospital with subacute onset
dizziness, confusion and gait instability leading to recur-
rent falls. She was subsequently admitted to the regional
tertiary neurological centre. On examination, she was
confused and disorientated, with a Mini Mental State
Examination score of 19 out of 30. She had oscillopsia
associated with bilateral, conjugate, involuntary, random
eye movements consistent with opsoclonus, mild dys-
arthria, titubation, upper limb myoclonus, left arm dys-
metria and a coarse intention tremor. She was not able
to sit upright due to a severe truncal ataxia. Her general
and systemic examination was normal. A putative diag-
nosis of OMS was made, and further investigations were
arranged in order to further investigate the cause.
Her full blood counts, C-reactive protein, liver and renal
function tests were normal. Blood cultures taken to iden-
tify an infective cause were negative. A paraneoplastic
antibody screen was negative for the following antibodies:
anti-neuronal nuclear antibodies type 1, anti- Hu, Purkinje
cell antibodies, anti-neuronal nuclear antibodies type II,
anti-Ma, anti-Tr, anti-amphiphysin, collapsin response
mediator protein-5, sex determining region Y-box 1 anti-
bodies, N-methyl D-aspartate antibodies, voltage gated
potassium channel antibodies, double-stranded DNA anti-
bodies, extractable nuclear antigen antibodies and anti-
neutrophil cytoplasmic antibodies. Tumor markers, in-
cluding cancer antigens 19–9 and 125, carcinoembryonic
antigen, alpha feta protein and human chorionic gonado-
tropin, were also all unremarkable. A traumatic lumbar
puncture tap contained a raised protein level of 0.71 and
occasional mononuclear cells. However, no organisms
were detected.
An MRI scan of her brain revealed a mass in the left
nasopharynx (3.4×2.5×2.6cm) with possible bony erosion
of the skull base. There was fluid collection in the left
mastoid air cells (Figure 1) and local mucosal enhance-
ment consistent with inflammatory disease. Subsequent
whole body (18F)-fluorodeoxyglucose positron emission
tomography (PET) did not reveal any other tumors, but
confirmed the presence of a nasopharyngeal mass and
an ipsilateral hypermetabolic level II lymph node
(1.5×1.4cm) (Figure 2).
Following identification of the mass, rigid nasoendoscopy
under general anaesthetic was performed, and showed a
pale bulky lesion in the post-nasal space blocking the leftEustachian tube. This was biopsied, and histological find-
ings showed fragments of a neoplasm, consisting of inter-
connecting cords of cells with a biphasic pattern (Figure 3).
The outer layer had a basaloid, spindled appearance, whilst
the inner cell clusters had more abundant, eosinophilic,
squamoid cytoplasm. Globules of pink amyloid-like protein
were present in both cell groups. The intervening stroma
contained a lymphoplasmacytic stromal infiltrate, which
also extended into the epithelium (Figure 4). Immunocyto-
chemistry showed positivity for MNF-116 and CAM5.2
(antibodies against epitopes expressed by different cytokera-
tins within epithelial cells); the latter also appeared to stain
the pink globules. The p63 antibody (a marker of squamous
differentiation expressed in basal and parabasal nuclei of
nasopharyngeal epithelium) predominantly stained the
outer basaloid layers whilst the S100 protein (a marker
present in neural, melanocytic and antigen presenting cells)
Figure 3 Representative area of the nasopharyngeal carcinoma
with interconnecting cords of paler epithelial cells (arrows)
surrounded by an outer layer of smaller ‘basaloid’ (arrow heads)
cells. (×10 magnification, hematoxylin and eosin stain).
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characteristic of a nasopharyngeal carcinoma.
She was treated with a three-day course of 1g methyl-
prednisolone (Pfizer Limited, Tadworth, Surrey, UK)
administered intravenously, followed by a tapering 60mg
dose of oral prednisolone (Actavis, Barnstaple, Devon,
UK) for several weeks for her neurological symptoms. She
also received five days of intravenous immunoglobulins
(IVIG) at a dose of 0.4g/kg/day (Biotest Pharma GmbH,
Landsteinerstr. 5 Dreieich, Germany). Her involuntary
movements and ataxia improved considerably, and in a
few weeks she was able to walk with a cane. But after one
month of receiving steroid treatment she developed a
psychotic episode, presumably related to the steroids, that
promptly responded to a reduction in steroid doses and
haloperidol. Following a referral to oncology she was
treated with chemoradiation: 70Gy in 35 fractions overFigure 4 Representative area of nasopharyngeal carcinoma at x20
magnification. The strands of malignant cells can be seen more
clearly. In addition to the pale cords and the darker basaloid cells,
scattered lymphocytes can be seen (the small dark cells scattered
throughout the image, arrows) and deposits of amyloid-like protein
(the pink globules forming a band at the top right of the image,
arrowheads). (×20 magnification, hematoxylin and eosin stain).seven weeks, using intensely modulated radiotherapy de-
livered by VMAC (Volumetric Arc Therapy, RapidArcTM,
Varian Medical Systems, Palo Alto, CA, USA) and three
cycles of concurrent cisplatin chemotherapy at a dose of
80mg/m2 per cycle. Four months from her diagnosis she
was able to sit upright without support. She still had rare
fragments of opsoclonus, which were asymptomatic. At
six months follow-up there were no signs of focal neuro-
logical deficit, apart from the inability to tandem walk.Discussion
The differential diagnosis of myoclonus and ataxia are
many, and include progressive cerebellar ataxia and myo-
clonus syndromes. However, the presence of opsoclonus
distinguishes the syndrome as OMS. To the best of our
knowledge, this is the first reported case of paraneoplastic
OMS occurring in association with a nasopharyngeal car-
cinoma. Although no paraneoplastic anti-neuronal anti-
body was found, we believe that the presence of a typical
paraneoplastic syndrome in association with a tumor and
an excellent resolution of symptoms are sufficient for the
diagnosis. This view is reinforced by Graus et al., who de-
fined the diagnostic criteria for paraneoplastic syndromes
[7]. Musunuru and Kesari [6] reported initial seronegativity
followed by seropositivity, leading us to speculate that an
as yet undescribed antibody may be responsible for OMS.
Childhood OMS exhibits a monophasic or chronic
relapsing pattern. It rarely regresses spontaneously, and
removal of a tumor, if present, is only sometimes curative
[8]. The current standard in children is the use of tapered
corticosteroids at 2mg/kg/day, or adrenocorticotropic hor-
mone (ACTH) [3]. IVIG and rituximab have been tried
with variable success. A combination of ACTH, IVIG and
rituximab, an example of multimodal immunosuppres-
sion, have led to relapse rates of 17% over six months,
which is much lower than for conventional agents alone
[9]. Further research is required on the treatment of OMS,
and two clinical trials exploring the use of steroids with ri-
tuximab or cyclophosphamide and tacrolimus are recruit-
ing at present [10,11].Conclusions
In this case report we highlight a hitherto unknown presen-
tation of a nasopharyngeal cancer as OMS. Small nasopha-
ryngeal lesions could be overlooked on brain imaging
scans, and will not be picked up on routine computed tom-
ography (CT) thorax, abdomen and pelvis scans used to try
to identify a paraneoplastic cause for OMS. Both neurolo-
gists and otorhinolaryngologists must be aware of such a
presentation. Where needed, careful search for a tumor
with a PET imaging scan should be considered in order to
identify cancers at a treatable stage, as in our patient.
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Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
Abbreviations
ACTH: Adrenocorticotropic hormone; IVIG: Intravenous immunoglobulin;
MRI: Magnetic resonance imaging; OMS: Opsoclonus-myoclonus syndrome;
PET: Positron emission tomography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BGT and AK both conceived the case report, searched the literature and
drafted the manuscript. PMM and LF reviewed the manuscript and made
substantial revisions to the article. LFo performed the histopathological
examination of the specimen and provided annotated slides for the paper.
DH provided an oncological perspective and revised the treatment section
of the article. TMJ and AJ both oversaw the creation of the article and made
substantial revisions to the drafts. All authors read and approved the final
manuscript.
Acknowledgements
The authors would like to extend their gratitude to the patient for her help
in completion of this article.
Author details
1Royal Liverpool Hospital University Hospital, Postgraduate Office, Prescot
Street, Liverpool L7 8XP, UK. 2Department of Otolaryngology, Head and Neck
Surgery, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK.
3Department of Neurology, Walton Centre NHS Foundation Trust, Lower
Lane, Liverpool L9 7LJ, UK. 4Department of Cellular Pathology, St Helens &
Knowsley NHS Trust, Marshalls Cross Road, Merseyside WA9 3DA, UK.
5Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road,
Wirral, Merseyside CH63 4JY, UK. 6Liverpool CR-UK Centre, University of
Liverpool, Daulby Street, Liverpool L69 3GA, UK.
Received: 1 January 2015 Accepted: 28 April 2015
References
1. Lozsadi D. Myoclonus: a pragmatic approach. Pract Neurol. 2012;12(4):215–24.
2. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg
Psychiatry. 1962;25(3):271.
3. Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-
myoclonus-ataxia syndrome. Curr Opin Pediatr. 2010;22(6):745–50.
4. Desai J, Mitchell WG. Acute cerebellar ataxia, acute cerebellitis, and
opsoclonus-myoclonus syndrome. J Child Neurol. 2012;27(11):1482–8.
5. Digre KB. Opsoclonus in adults - report of 3 cases and review of the
literature. Arch Neurol. 1986;43(11):1165–75.
6. Musunuru K, Kesari S. Paraneoplastic opsoclonus-myoclonus ataxia associated
with non small-cell lung carcinoma. J Neurooncol. 2008;90(2):213–6.
7. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al.
Recommended diagnostic criteria for paraneoplastic neurological
syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.
8. Suchowersky O, Comella C. Hyperkinetic movement disorders. 1st ed.
New York, USA: Humana Press; 2012. p. 350.
9. Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell
expansion in opsoclonus-myoclonus syndrome: a biomarker of disease
activity. Mov Disord. 2004;19(7):770–7.10. Orange D, Frank M, Tian S, Dousmanis A, Marmur R, Buckley N, et al.
Immunotherapy of the Paraneoplastic Syndromes. Rockefeller University,
New York, USA. Trial identifier: NCT00378326. ClinicalTrials.gov. Opsoclonus
USA: National Library of Medicine 2014 [updated May 2014; cited 2014 17/
05/2014]. Available from: https://clinicaltrials.gov/ct2/show/
NCT00378326?term=opsoclonus&rank=6.
11. Tresca P, Faure Conter C, Coze C, Haouy S, Diop M, Fasola S, et al.
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in
Children With and Without Neuroblastoma (NBpos and NBneg) Opsoclonus
Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With
and Without Neuroblastoma (NBpos and NBneg). Institut Curie, France. Trial
Identifier:NCT01868269. Clinical Trials.gov. Opsoclonus USA: National Library
of Medicine 2014 [updated May 2014; cited 2014 17/05/2014]. Available
from: https://clinicaltrials.gov/ct2/show/NCT01868269?term=opsoclonus&rank=3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
